2022年4月30日，吉(ji)林紫鑫药(yao)(yao)(yao)业股(gu)(gu)(gu)(gu)(gu)(gu)份有(you)(you)限(xian)公(gong)(gong)司(si)（下(xia)(xia)称紫鑫药(yao)(yao)(yao)业，股(gu)(gu)(gu)(gu)(gu)(gu)票代码：002118）通过深圳证券(quan)交易所(suo)官网披露《吉(ji)林紫鑫药(yao)(yao)(yao)业股(gu)(gu)(gu)(gu)(gu)(gu)份有(you)(you)限(xian)公(gong)(gong)司(si)详式权益变动(dong)报告书(shu)》（下(xia)(xia)称《权益变动(dong)报告书(shu)》），国(guo)药(yao)(yao)(yao)兆(zhao)祥(xiang)（长春）医(yi)药(yao)(yao)(yao)有(you)(you)限(xian)公(gong)(gong)司(si)（下(xia)(xia)称国(guo)药(yao)(yao)(yao)兆(zhao)祥(xiang)）作为信息披露义务人，对其实际控(kong)制(zhi)(zhi)人情况披露如下(xia)(xia)：“中国(guo)医(yi)药(yao)(yao)(yao)集(ji)团有(you)(you)限(xian)公(gong)(gong)司(si)持有(you)(you)中国(guo)中药(yao)(yao)(yao)有(you)(you)限(xian)公(gong)(gong)司(si)100%股(gu)(gu)(gu)(gu)(gu)(gu)权；中国(guo)中药(yao)(yao)(yao)有(you)(you)限(xian)公(gong)(gong)司(si)持有(you)(you)国(guo)药(yao)(yao)(yao)药(yao)(yao)(yao)材(cai)(cai)股(gu)(gu)(gu)(gu)(gu)(gu)份有(you)(you)限(xian)公(gong)(gong)司(si)25%股(gu)(gu)(gu)(gu)(gu)(gu)权，为国(guo)药(yao)(yao)(yao)药(yao)(yao)(yao)材(cai)(cai)股(gu)(gu)(gu)(gu)(gu)(gu)份有(you)(you)限(xian)公(gong)(gong)司(si)第一大股(gu)(gu)(gu)(gu)(gu)(gu)东(dong)，同时根据国(guo)药(yao)(yao)(yao)药(yao)(yao)(yao)材(cai)(cai)股(gu)(gu)(gu)(gu)(gu)(gu)份有(you)(you)限(xian)公(gong)(gong)司(si)股(gu)(gu)(gu)(gu)(gu)(gu)东(dong)会决议(yi)和公(gong)(gong)司(si)章程，中国(guo)中药(yao)(yao)(yao)有(you)(you)限(xian)公(gong)(gong)司(si)委(wei)派(pai)选举的董事(shi)占其董事(shi)会半数(shu)以上，形成实际控(kong)制(zhi)(zhi)；国(guo)药(yao)(yao)(yao)药(yao)(yao)(yao)材(cai)(cai)股(gu)(gu)(gu)(gu)(gu)(gu)份有(you)(you)限(xian)公(gong)(gong)司(si)持有(you)(you)国(guo)药(yao)(yao)(yao)兆(zhao)祥(xiang)100%股(gu)(gu)(gu)(gu)(gu)(gu)权。中国(guo)医(yi)药(yao)(yao)(yao)集(ji)团有(you)(you)限(xian)公(gong)(gong)司(si)为国(guo)药(yao)(yao)(yao)兆(zhao)祥(xiang)实际控(kong)制(zhi)(zhi)人”。
我公司认为，上述信息严重不实。兹严正(zheng)声明如下：
1.中(zhong)国中(zhong)药(yao)(yao)有(you)(you)限公司(si)仅持有(you)(you)国药(yao)(yao)药(yao)(yao)材股(gu)份(fen)有(you)(you)限公司(si)（下称(cheng)药(yao)(yao)材股(gu)份(fen)）25%的(de)股(gu)份(fen)，不是药(yao)(yao)材股(gu)份(fen)的(de)控股(gu)股(gu)东；
2.自2016年11月股(gu)(gu)(gu)权比例减持至25%以(yi)(yi)(yi)来，在中(zhong)国中(zhong)药(yao)有限公司(si)参与(yu)审议通过的(de)药(yao)材(cai)(cai)股(gu)(gu)(gu)份(fen)股(gu)(gu)(gu)东大会决(jue)议以(yi)(yi)(yi)及参与(yu)制定、修改的(de)公司(si)章(zhang)程中(zhong)，没有中(zhong)国中(zhong)药(yao)有限公司(si)委派(pai)的(de)董(dong)事(shi)(shi)占药(yao)材(cai)(cai)股(gu)(gu)(gu)份(fen)董(dong)事(shi)(shi)会半(ban)(ban)数(shu)以(yi)(yi)(yi)上(shang)的(de)规定。中(zhong)国中(zhong)药(yao)有限公司(si)也从未(wei)向药(yao)材(cai)(cai)股(gu)(gu)(gu)份(fen)董(dong)事(shi)(shi)会委派(pai)占其半(ban)(ban)数(shu)以(yi)(yi)(yi)上(shang)的(de)董(dong)事(shi)(shi)；
3.无论是我公司还是中国中药有限公司，均不是药材股份的实际控制人，更不是国药兆祥的实际控制人；
4.由于(yu)药(yao)材股(gu)(gu)份未(wei)履(lv)行(xing)股(gu)(gu)东(dong)(dong)大(da)会(hui)会(hui)议(yi)召集程(cheng)(cheng)序(xu)，虚构股(gu)(gu)东(dong)(dong)大(da)会(hui)会(hui)议(yi)，伪造股(gu)(gu)东(dong)(dong)大(da)会(hui)决(jue)议(yi)及董事(shi)签字，擅(shan)自(zi)修改公(gong)司章程(cheng)(cheng)，中国中药(yao)有限公(gong)司已(yi)于(yu)2022年3月31日向北京市海(hai)淀(dian)区人(ren)民法院提(ti)起诉讼（案(an)件(jian)编号：（2022）海(hai)预(yu)民字第38299号）；
5.我公(gong)司将向证(zheng)券监(jian)督(du)管理机(ji)关及公(gong)安机(ji)关举报(bao)国药兆祥的违(wei)(wei)法违(wei)(wei)规披露(lu)行为，请求上述机(ji)关依法严(yan)厉(li)追(zhui)究相关责任(ren)主体的法律(lv)责任(ren)。
请各位投(tou)资者(zhe)对于《权益变动(dong)报告书(shu)》所(suo)载(zai)内容(rong)进行严格(ge)审查，避免利益受损。
特此声明。
中国医药(yao)集团(tuan)有限公司(si)
2022年(nian)4月30日(ri) ;
